| Drug Name |
Alprostadil |
| Drug ID |
BADD_D00086 |
| Description |
Alprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology. |
| Indications and Usage |
For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology. |
| Marketing Status |
approved; investigational |
| ATC Code |
C01EA01; G04BE01 |
| DrugBank ID |
DB00770
|
| KEGG ID |
D00180
|
| MeSH ID |
D000527
|
| PubChem ID |
5280723
|
| TTD Drug ID |
D0I4DQ
|
| NDC Product Code |
0037-8120; 0037-8130; 0037-8140; 68245-0007; 73212-075; 45542-1152; 49452-0073; 40016-010; 0009-3701; 0009-5182; 52244-020; 82231-101; 0009-3169; 0009-5181; 63539-221; 0009-0042; 51552-0498; 51927-2196; 71052-146; 63539-121; 63902-100; 0009-0215; 52244-010; 52244-040; 38779-0944; 65035-101; 0009-7686 |
| UNII |
F5TD010360
|
| Synonyms |
Alprostadil | PGE1alpha | Prostaglandin E1alpha | PGE1 | Lipo-PGE1 | Lipo PGE1 | Prostaglandin E1 | Caverject | Edex | Prostavasin | Muse | Viridal | Vasaprostan | Minprog | Sugiran | Prostin VR | Prostine VR |
